|
It is the goal of Bavarian Nordic to be a leading supplier of innovative vaccines for the treatment and prevention of life-threatening diseases. In addition, the Company seeks to create shareholder value by ensuring sustained profitable operations, by focusing its development activities and by optimising the resources used.
The Company’s pipeline currently includes a total of six development programmes in the following three areas: biodefense, cancer and infectious diseases.
All programmes are subjected to an overall pragmatic, data-driven prioritisation strategy so that future favourable or unfavourable data will be decisive factors for the individual programmes.
Biodefense
This is the Company’s principal area of business. The strategy for this area focuses on handling the entire value chain, all the way from development to production and sale of vaccines.
One goal is to complete the clinical development of IMVAMUNE® in the run-up to registration. The vaccine will then be commercialised via sales to the United States and other countries.
In addition, the intention is to build up a biodefense portfolio of projects that can complement IMVAMUNE® and ensure the Company a sustained and growing business.
Cancer
In the short term, the goal is to complete the Phase I/II studies of the vaccine candidates for breast and prostate cancer.
As and when positive clinical data are obtained, partnering of the projects will be considered and the Company will also keep an eye on potential in-licensing opportunities.
Infectious diseases
The Company has a number of projects in infectious diseases, all of which are at an early development stage: HIV, measles/RSV, dengue fever and Japanese encephalitis.
The goal with the first two projects is to complete early-stage clinical trials. If supported by the data obtained, the option of placing these projects in external partnerships will be explored. Alternatively, the Company will seek other external funding. For the latter two projects, discussions with a potential external partner on clinical development and funding are pending.
The programme for measles/RSV will be tested up to and through clinical Phase I, where it is expected that proof of concept will be obtained. As for HIV multiantigen, Phase I/II clinical studies will be completed, and partnering negotiations will be initiated as and when the project progresses.
Patent and partner strategy
Bavarian Nordic seeks to strengthen and build on existing patent portfolio to support and expand the IP position on MVA-BN®. The Company furthermore seeks appropriate opportunities to strengthen the IP position on MVA through partnership/licensing agreements. If partnerships/licensing agreements cannot be obtained, Bavarian Nordic will vigorously defend the IP position on MVA to prevent infringement from occurring.
|
